Structure-guided development of covalent TAK1 inhibitors.
Tan, L., Gurbani, D., Weisberg, E.L., Hunter, J.C., Li, L., Jones, D.S., Ficarro, S.B., Mowafy, S., Tam, C.P., Rao, S., Du, G., Griffin, J.D., Sorger, P.K., Marto, J.A., Westover, K.D., Gray, N.S.(2017) Bioorg Med Chem 25: 838-846
- PubMed: 28011204 
- DOI: https://doi.org/10.1016/j.bmc.2016.11.035
- Primary Citation of Related Structures:  
5E7R, 5J7S, 5J8I, 5J9L, 5JH6, 5JK3 - PubMed Abstract: 
TAK1 (transforming growth factor-β-activated kinase 1) is an essential intracellular mediator of cytokine and growth factor signaling and a potential therapeutic target for the treatment of immune diseases and cancer. Herein we report development of a series of 2,4-disubstituted pyrimidine covalent TAK1 inhibitors that target Cys174, a residue immediately adjacent to the 'DFG-motif' of the kinase activation loop ...